[Serotonin syndrome].
Yamawaki
Shigeto
S
Department of Psychiatry and Neurosciences, Graduate School of Biomedical Sciences, Hiroshima University.
Iwamoto
Yasuyuki
Y
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects*; D000818:Animals; D003521:Cyclopropanes / Q000009:adverse effects; D003533:Cyproheptadine / Q000627:therapeutic use; D003937:Diagnosis, Differential; D016666:Fluvoxamine / Q000009:adverse effects; D006801:Humans; D000078764:Milnacipran; D012015:Reference Standards; D012702:Serotonin Antagonists / Q000627:therapeutic use; D020230:Serotonin Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D018759:Adrenergic Uptake Inhibitors; D003521:Cyclopropanes; D003533:Cyproheptadine; D016666:Fluvoxamine; D000078764:Milnacipran; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors